North China Gains OK For Fidaxomicin Trials
This article was originally published in PharmAsia News
Executive Summary
The China FDA has announced that the application for clinical trials for the Class 3.1 antibiotic fidaxomicin API and tablets by North China Pharmaceutical Group (NCPC) has been accepted.